Case report: Liquid biopsy, the sooner the better?

Case report: Liquid biopsy, the sooner the better?

The detection of circulating tumor DNA (ctDNA) by liquid biopsy is taking an increasing role in thoracic oncology management due to its predictive and prognostic value. For non-small cell lung cancer, it allows the detection of molecular mutations that can be targeted with tyrosine kinase inhibitors...

Full description

Bibliographic Details
Main Authors: Quentin Dominique Thomas, Julien Colard-Thomas, Delphine Delansay, Fanny Leenhardt, Jerome Solassol, Julie A. Vendrell, Xavier Quantin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Oncology
Subjects:
lung cancer
ctDNA = circulating tumor DNA
liquid biopsy
EGFR
thrombotic microangiopathy (TMA)
osimertinib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1089108/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1089108/full

Similar Items